section name header

Pronunciation ⬇

tas-i-MEL-tee-on

Classifications ⬆ ⬇

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: melatonin receptor agonists

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Acts as an agonist at melatonin MT1 and MT2 receptor sites, which are involved in regulation or circadian rhythm.
Therapeutic effects:
  • Improved circadian rhythm with improved sleep/wake patterns.

Pharmacokinetics ⬆ ⬇

Absorption: 38% absorbed following oral administration, plasma concentrations ↑ in female patients.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP1A2 and CYP3A4 isoenzymes. Primarily excreted in urine as metabolites.

Half-Life: 1.3 hr.

Time/Action Profile ⬆ ⬇

(establishment of circadian rhythm/sleep cycle)

ROUTEONSETPEAKDURATION
POwks–mosunknownunknown



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

GI: ↑liver enzymes

Neuro: headache, nightmares/unusual dreams

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Non-24-Hour Sleep-Wake Disorder

Nighttime Sleep Disturbances in Smith-Magenis Syndrome

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Hetlioz, Hetlioz LQ